Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease.
Manson
A J
AJ
The Reta Lila Weston Institute of Neurological Studies, University College London, Windeyer Institute of Medical Science, UK.
Iakovidou
E
E
Lees
A J
AJ
D000284:Administration, Oral; D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D019329:Idazoxan / Q000009:adverse effects / Q000627:therapeutic use*; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy*; D017211:Treatment Failure
D000317:Adrenergic alpha-Antagonists; D000978:Antiparkinson Agents; D007980:Levodopa; D019329:Idazoxan